Skip to main content
  • Contact Us
  • Vantage logo Sign Up
  • Subscriber Sign In
Evaluate Logo

navigation

  • What We Do
    • Commercial Intelligence
    • Products
      • Evaluate Pharma
      • Evaluate Omnium
      • Evaluate Medtech
      • Evaluate Epi
      • Japan Drug Forecasts
      • Europe Drug Forecasts
    • Pharma Consulting & Analytics
      • Pharma Consulting & Analytics
      • Data Feeds
    • Evaluate Vantage
      • News
      • Analysis
      • Policy & Pricing
      • Insights
      • Events
      • Medtech
      • Therapy Areas
      • Editorial Team
      • About Evaluate Vantage
    • Evaluate for Biotech
  • How We Can Help You
    • Pharma and Biotech
    • Financial Services
    • Management Consultancies
    • Service Providers
    • Customer Testimonials
  • Thought Leadership
    • Multimedia
    • Blog
  • About Us
    • Press Releases
    • Media Coverage
    • Executive Team
    • Vision & History
  • Contact Us
  • Sign Up for Evaluate Vantage
  • Talent
  • Subscriber Sign In

 

Vantage logo

Vantage

  • Covid-19
    • Covid-19 Coverage
    • Evaluate Vantage COVID-19 Report
  • News
    • Snippets
    • Deals
    • Trial results
    • Patents and litigation
    • Corporate strategy
  • Analysis
    • Interviews
    • Spotlight
    • Vantage points
    • Vantage views
  • Insights
    • M&A
    • IPO
    • NME approvals
    • Quarterly shareprice performance
    • Venture financing
    • Vantage data points
    • Other data
  • Events
    • Company events
    • Conferences
    • Upcoming events
  • Medtech
  • Therapy Areas
  • About
    • Editorial team

Breadcrumb

  1. Home
  2. Vantage
  3. Topics
  4. Market Status

Market Status

Evaluate

Thumbnail
March 23, 2023

Tofersen adcom raises hopes of even more FDA flexibility

Thumbnail
March 23, 2023

Dupixent pushes towards a big new use

Article image
Vantage logo
March 22, 2023

89Bio Enlivened by Nash success

The company follows Madrigal and Akero with a clinical hit.

Article image
Vantage logo
March 22, 2023

Second pivotal hit brings Claudin18.2 closer to approval

Article image
Vantage logo
March 21, 2023

Obesity dropouts hurt Altimmune

The company’s value is cut in half as mid-stage data prove a let-down.

Article image
Vantage logo
March 20, 2023

AAD 2023 – Takeda outdoes Bristol’s Sotyktu

TAK-279 comes out on top in the battle of the Tyk2 inhibitors, but biologicals still rule.

Article image
Vantage logo
March 20, 2023

AAD 2023 – UCB and Acelyrin take aim at hidradenitis suppurativa

But Humira remains the one to beat.

Article image
Vantage logo
March 17, 2023

Bad vibes continue for Merck

Article image
Vantage logo
March 17, 2023

Sarepta investors fear a panel beating

Article image
Vantage logo
March 15, 2023

Illumina investors give long reads short shrift

Article image
Vantage logo
March 14, 2023

Amylyx aces launch as tofersen’s big date approaches

Breakeven beckons for Amylyx.

  • Load More
Vantage logo
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up

Latest Reports

February 17, 2023

PD(L)anner – February 2023

February 09, 2023

Biopharma and Medtech Review 2022

View more...

Editor's Picks

Vantage logo
March 13, 2023

Silicon Valley Bank: biopharma’s latest crisis

Vantage logo
March 13, 2023

Pfizer rescues biotech

Vantage logo
February 28, 2023

Why Pfizer (and others) will be interested in Seagen

Vantage logo
March 04, 2023

ACC 2023 – Esperion’s outcomes win looks lacklustre

Vantage logo
March 06, 2023

T-cell receptor behemoths consolidate? Not quite

Open modal

Evaluate Logo

Evaluate HQ
44-(0)20-7377-0800

Evaluate Americas
+1-617-573-9450

Evaluate APAC
+81-80-1164-4754

Footer menu

  • Terms and conditions
  • Privacy Policies
  • Cookie Policy
  • Modern Slavery Statement

© Copyright 2023 Evaluate Ltd.

Sign up